December 11 – Dr. Nicholas Zdenkowski
Dr. Nick Zdenkowski discusses the EMBER trial on second-line ER-targeted drugs, patient-reported outcome monitoring, and the survival benefits of risk-reducing surgeries for BRCA mutant patients.
December 11 – Dr. Nicholas Zdenkowski Read More »